|drug945||Cloth Face Mask Wiki||1.00|
|drug2460||N-95 Respirator Wiki||1.00|
|drug1646||Graded exercise test Wiki||1.00|
There is one clinical trial.
The purpose of this proposed project is to test whether several biological factors (such as elevated brain reward region and attention region response to high-calorie foods, weaker inhibitory region response to high-calorie foods, habitual caloric deprivation, and elevated limbic region responsivity) increase the risk of problematic eating (bingeing and purging) in female adolescents.
Description: Eating Disorder Diagnostic Interview (EDDI)Measure: Change in binge eating behaviors using the EDDI Time: 6 months, 1 year, 2 year, and 3 year follow-up
Description: Eating Disorder Diagnostic Interview (EDDI)Measure: Change in compensatory behaviors using the EDDI Time: 6 months, 1 year, 2 year, and 3 year follow-up
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports